A gatekeeper against insulin resistance in the brain

August 21, 2020

The brain plays a major role in controlling our blood glucose levels. In type 2 diabetics this glucose metabolism brain control is often dysfunctional. Genetic components for this phenomenon have so far remained elusive. A group of scientists at Helmholtz Zentrum München and the German Center for Diabetes Research (DZD) have now shown in the Journal of Clinical Investigations that in men a genetic variant of the gene DUSP8 can increase the risk for type 2 diabetes by impairing our brain response to the hormone insulin.

Insulin is a pancreatic hormone that controls our blood sugar levels. Insulin not only stimulates the uptake of glucose from blood into peripheral tissues, it also acts on the brain, specifically the hypothalamus, to control glucose and energy metabolism. In obese subjects, insulin loses some of its activity due to the activation of inflammatory signaling and a subsequent impairment of the cellular response downstream to the insulin receptor. This phenomenon, termed insulin resistance, is a major hallmark in the development of type 2 diabetes, but to date not yet fully understood. Recent genome-wide association studies (GWAS) identified DUSP8 as type 2 diabetes risk gene. Now, scientists have investigated how the protein Dusp8 (dual-specificity phosphatase 8), which is encoded by the DUSP8 gene, regulates glucose tolerance and insulin sensitivity.

Genetic variant of the DUSP8 gene increases risk of type 2 diabetes

"Carriers of a genetic variant of the gene DUSP8 were shown to have a moderately increased risk for type 2 diabetes, but the functional importance of Dusp8 for the etiology of the disease remained unknown," explains Dr. Sonja C. Schriever, lead author of the study. "By combining cellular models, Dusp8 loss- and gain-of-function mice and functional magnetic resonance imaging (fMRI) of humans with genetic variants in the gene DUSP8, we now exposed a specific role of the protein Dusp8 as a gatekeeper for systemic glucose tolerance and hypothalamic insulin sensitivity," adds colleague and senior author Prof. Dr. Paul Pfluger. Within the framework of the German Center for Diabetes Research (DZD), both scientists formed a team of biologists, epidemiologists and clinicians that was able to unravel the molecular mechanisms that link Dusp8 with the development of type 2 diabetes.

Protein Dusp8 has regulatory effects on hypothalamic insulin sensitivity

The protein Dusp8 has a regulatory effect on inflammatory processes in the hypothalamus and on the hypothalamic-pituitary-adrenal (HPA) axis. It seems to protect the organism against hyper-activation of inflammatory signaling and impaired insulin sensitivity in the hypothalamus. The scientists could show that the deletion of the Dusp8 gene in male but not in female mice increased hypothalamic inflammation, impaired HPA axis feedback and increased basal stress hormone levels, which all together aggravated the insulin sensitivity. The sex-specific role of murine Dusp8 was consistent with fMRI data in human volunteers that revealed reduced hypothalamic insulin sensitivity in male but not female carriers of the DUSP8 type 2 diabetes risk variant.

"Unraveling the multi-systemic processes that drive the impaired hypothalamic insulin sensitivity in the mouse models was an important step to understand the mechanistic underpinnings of the type 2 diabetes risk gene DUSP8", concludes Schriever. In future studies, the researchers want to investigate the effect of central insulin action and the DUSP8 type 2 diabetes risk variant on the hypothalamic-pituitary-adrenal axis in human subjects with or without T2D.
-end-
Original publication:

Schriever SC et. al.: Type 2 diabetes risk gene Dusp8 regulates hypothalamic Jnk signaling and insulin sensitivity. J Clin Invest. 2020 Aug 11:136363. doi: 10.1172/JCI136363. PMID: 32780722.

Scientific contact:

Prof. Dr. Paul Pfluger
Helmholtz Zentrum München - German Research Center for Environmental Health
Research Unit NeuroBiology of Diabetes and Neurobiology of Diabetes, TUM School of Medicine, Technical University of Munich
Ingolstädter Landstr. 1,
85764 Neuherberg
Phone +49 89 3187 2104
E-mail: paul.pfluger(at)helmholtz-muenchen.de

The Research Unit NeuroBiology of Diabetes (NBD) at Helmholtz Zentrum München studies the role of the central nervous system (CNS) as potential common denominator for obesity and diabetes type 2. NBD, which is associated with the IDO and part of the HDC and DZD, aims to understand the exact molecular underpinnings for leptin resistance and weight cycling and our adaptive physiological response to changes in the environment. http://www.helmholtz-muenchen.de/nbd

The Helmholtz Zentrum München, the German Research Center for Environmental Health, pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes, allergies and lung diseases. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle. The Helmholtz Zentrum München is headquartered in Neuherberg in the north of Munich and has about 2,300 staff members. It is a member of the Helmholtz Association, a community of 18 scientific-technical and medical-biological research centers with a total of about 37,000 staff members. http://www.helmholtz-muenchen.de/en

The German Center for Diabetes Research (DZD) is one of six German centers of health research. It brings together experts in the field of diabetes research and combines basic research, epidemiology and clinical applications. Using a novel, integrative research approach, the DZD seeks to make a major contribution to developing a successful, personalized prevention, diagnosis and treatment of diabetes mellitus. The members of the network are Helmholtz Zentrum München - German Research Center for Environmental Health, the German Diabetes Center (DDZ) in Düsseldorf, the German Institute of Human Nutrition (DIfE) in Potsdam-Rehbrücke, the Institute for Diabetes Research and Metabolic Diseases of Helmholtz Zentrum München at the University of Tübingen and the Paul Langerhans Institute Dresden of Helmholtz Zentrum München at the TU Dresden Medical Center, associated partners at the universities in Heidelberg, Cologne, Leipzig, Lübeck and Munich as well as additional project partners. https://www.dzd-ev.de/en

Deutsches Zentrum fuer Diabetesforschung DZD

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.